Showing 1831-1840 of 2652 results for "".
- NYU Med School Will Graduate Students Early to Help New York Fight Coronavirushttps://modernod.com/news/nyu-med-school-will-graduate-students-early-to-help-new-york-fight-coronavirus/2477471/As COVID-19 continues to slam New York City hospitals, New York University’s Grossman School of Medicine this week took the dramatic step of letting its graduating class depart early to join the response effort, according to a TIME
- EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-phase-3-study-of-yutiq/2477336/EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second phase 3 trial of Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. “The d
- Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for AMDhttps://modernod.com/news/gemini-therapeutics-and-singapore-eye-research-institute-enter-into-research-collaboration-to-explore-new-targets-for-amd/2477327/Gemini Therapeutics announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and potential biomarkers in patients d
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- CRST: 2019 Year in Focushttps://modernod.com/news/2019-year-in-focus/2477197/Fueled by an influx of investment capital in recent years and a streamlined regulatory review process, the number of ophthalmic products approved or introduced in 2019 continued to rise steadily throughout the year. According to recent figures from pharmaceutical market research company Strategic
- 10 Best Foods to Protect Your Eyesighthttps://modernod.com/news/10-best-foods-to-protect-your-eyesight/2477196/As we approach the new year and new decade, many of us are focused on a new vision for our lives. But in order to protect the vision we have, experts say that eating certain foods can help us preserve our eyesight and prevent ocular diseases. “Antioxidants have been long known to hel
- Nidek Launches the YC-200 and YC-200 S Plus in the United Stateshttps://modernod.com/news/nidek-launches-the-yc-200-and-yc-200-s-plus-in-the-united-states/2477101/Nidek has announced that the FDA has issued 510(k) clearance for the YC-200 Ophthalmic YAG Laser System. The YC-200 includes the S plus model for Selective Laser Trabeculoplasty (SLT). With FDA clearance, the YC-200 and YC-200 S plus are now commercially available in the United States. The
- EyePoint Pharmaceuticals Announces Addition of Dexycu and Yutiq to Department of Veteran Affairs Federal Supply Schedulehttps://modernod.com/news/eyepoint-pharmaceuticals-announces-addition-of-dexycu-and-yutiq-to-department-of-veteran-affairs-federal-supply-schedule/2477065/EyePoint Pharmaceuticals announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs (VA) for Dexycu and Yutiq to be included on the Federal Supply Schedule (FSS), providing U.S. veterans and other federal government agencies with access to both products. The VA
- Cataract Surgery Can Make You 48 Percent Safer on the Roadhttps://modernod.com/news/cataract-surgery-can-make-you-48-percent-safer-on-the-road/2477000/The ability of cataract surgery to restore sight is well known. People say they’re stunned by the vibrancy of color after surgery and the improvement in night vision. Some can even reduce their reliance on glasses. But can you quantify that improved quality of vision? To find out, researchers in